AI Tokens
Stock Analysis on Net

IQVIA Holdings Inc. (NYSE:IQV)

This company has been moved to the archive! The financial data has not been updated since November 1, 2023.

Analysis of Long-term (Investment) Activity Ratios

Microsoft Excel

Long-term Activity Ratios (Summary)

IQVIA Holdings Inc., long-term (investment) activity ratios

Microsoft Excel
Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
Net fixed asset turnover 18.94 20.31 18.81 24.21 23.99
Net fixed asset turnover (including operating lease, right-of-use asset) 13.20 12.74 10.57 11.62 23.99
Total asset turnover 0.57 0.56 0.46 0.48 0.46
Equity turnover 2.50 2.30 1.89 1.85 1.55

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).


The company's investment activity ratios exhibit a divergence between fixed asset efficiency and overall asset utilization. While fixed asset turnover has experienced volatility and a general decline, total asset and equity turnovers have shown a steady upward trend, indicating an improvement in the company's ability to generate revenue from its broader resource base.

Asset Utilization Efficiency
Total asset turnover increased from 0.46 in 2018 to 0.57 by 2022, with a notable acceleration occurring between 2020 and 2021. Parallel to this, equity turnover grew consistently from 1.55 in 2018 to 2.50 in 2022, reflecting a significant increase in the efficiency with which shareholder equity is utilized to drive revenue generation.
Fixed Asset Performance
Net fixed asset turnover peaked at 24.21 in 2019 before experiencing a downward trend to 18.94 by 2022. When incorporating operating lease right-of-use assets, the ratio saw a sharp contraction from 23.99 in 2018 to 10.57 in 2020, followed by a gradual recovery to 13.20 by the end of 2022. This suggests a substantial expansion of the right-of-use asset base relative to revenue growth during the early part of the period.
Comparative Analysis of Investment Trends
The contrast between the declining fixed asset turnover and the rising total asset turnover suggests that the growth in specific long-term assets—particularly leased assets—has not negatively impacted overall operational productivity. The continuous upward trajectory of equity turnover indicates a strategic shift toward higher capital efficiency and a more aggressive utilization of equity to expand the top line.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Net Fixed Asset Turnover

IQVIA Holdings Inc., net fixed asset turnover calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
Selected Financial Data (US$ in millions)
Revenues 14,410 13,874 11,359 11,088 10,412
Property and equipment, net, including finance lease right-of-use assets 761 683 604 458 434
Long-term Activity Ratio
Net fixed asset turnover1 18.94 20.31 18.81 24.21 23.99
Benchmarks
Net Fixed Asset Turnover, Competitors2
AbbVie Inc. 11.76 11.00 — — —
Amgen Inc. 4.57 4.69 — — —
Bristol-Myers Squibb Co. 7.38 7.67 — — —
Danaher Corp. 7.96 7.77 — — —
Eli Lilly & Co. 2.81 3.15 — — —
Gilead Sciences Inc. 4.93 5.27 — — —
Johnson & Johnson 4.79 4.95 — — —
Merck & Co. Inc. 2.77 2.53 — — —
Pfizer Inc. 6.22 5.52 — — —
Regeneron Pharmaceuticals Inc. 3.23 4.62 — — —
Thermo Fisher Scientific Inc. 4.84 4.71 — — —
Vertex Pharmaceuticals Inc. 8.06 6.92 — — —
Net Fixed Asset Turnover, Sector
Pharmaceuticals, Biotechnology & Life Sciences 4.98 4.98 — — —
Net Fixed Asset Turnover, Industry
Health Care 7.88 7.74 — — —

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

1 2022 Calculation
Net fixed asset turnover = Revenues ÷ Property and equipment, net, including finance lease right-of-use assets
= 14,410 ÷ 761 = 18.94

2 Click competitor name to see calculations.


The analysis of long-term activity indicates a period of significant asset expansion alongside steady revenue growth between 2018 and 2022. While total revenues increased consistently, the efficiency of net fixed asset utilization experienced notable volatility, suggesting that capital expenditures grew at a faster pace than revenue generation during specific intervals.

Revenue and Asset Growth Patterns
Revenues grew from 10,412 million US$ in 2018 to 14,410 million US$ in 2022, representing a consistent upward trajectory. Simultaneously, property and equipment, net, increased from 434 million US$ to 761 million US$, reflecting a substantial investment in the long-term asset base over the five-year period.
Net Fixed Asset Turnover Volatility
The net fixed asset turnover ratio exhibited a peak of 24.21 in 2019 before experiencing a sharp decline to 18.81 in 2020. This contraction in 2020 corresponds with a significant increase in net fixed assets, which rose by approximately 32% in a single year, outpacing the marginal revenue growth of that period.
Efficiency Recovery and Stabilization
A recovery in asset efficiency occurred in 2021, with the ratio rising to 20.31. This improvement was driven by a substantial surge in revenues to 13,874 million US$, which effectively leveraged the previous year's capital investments. However, by 2022, the ratio declined again to 18.94, as further increases in net fixed assets once more offset the gains in revenue growth.
Long-term Operational Insight
The overall trend indicates that while the organization has successfully expanded its top-line revenue, the efficiency of its fixed asset base has diminished since 2019. The shift from a turnover ratio of 23.99 in 2018 to 18.94 in 2022 suggests a transition toward a more asset-intensive operational model.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Net Fixed Asset Turnover (including Operating Lease, Right-of-Use Asset)

IQVIA Holdings Inc., net fixed asset turnover (including operating lease, right-of-use asset) calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
Selected Financial Data (US$ in millions)
Revenues 14,410 13,874 11,359 11,088 10,412
 
Property and equipment, net, including finance lease right-of-use assets 761 683 604 458 434
Operating lease right-of-use assets 331 406 471 496 —
Property and equipment, net, including finance lease right-of-use assets (including operating lease, right-of-use asset) 1,092 1,089 1,075 954 434
Long-term Activity Ratio
Net fixed asset turnover (including operating lease, right-of-use asset)1 13.20 12.74 10.57 11.62 23.99
Benchmarks
Net Fixed Asset Turnover (including Operating Lease, Right-of-Use Asset), Competitors2
AbbVie Inc. 10.24 9.57 — — —
Amgen Inc. 4.13 4.23 — — —
Bristol-Myers Squibb Co. 6.18 6.66 — — —
Danaher Corp. 6.35 6.10 — — —
Eli Lilly & Co. 2.63 2.93 — — —
Gilead Sciences Inc. 4.51 4.77 — — —
Johnson & Johnson 4.54 4.72 — — —
Merck & Co. Inc. 2.60 2.33 — — —
Pfizer Inc. 5.25 4.64 — — —
Regeneron Pharmaceuticals Inc. 3.17 4.52 — — —
Thermo Fisher Scientific Inc. 4.13 3.98 — — —
Vertex Pharmaceuticals Inc. 6.13 5.32 — — —
Net Fixed Asset Turnover (including Operating Lease, Right-of-Use Asset), Sector
Pharmaceuticals, Biotechnology & Life Sciences 4.48 4.45 — — —
Net Fixed Asset Turnover (including Operating Lease, Right-of-Use Asset), Industry
Health Care 6.90 6.75 — — —

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

1 2022 Calculation
Net fixed asset turnover (including operating lease, right-of-use asset) = Revenues ÷ Property and equipment, net, including finance lease right-of-use assets (including operating lease, right-of-use asset)
= 14,410 ÷ 1,092 = 13.20

2 Click competitor name to see calculations.


Revenues exhibited a consistent upward trajectory from 2018 to 2022, increasing from US$ 10,412 million to US$ 14,410 million. This growth occurred alongside a significant expansion of the asset base, specifically in property and equipment, including right-of-use assets. A substantial increase is noted between 2018 and 2019, where assets rose from US$ 434 million to US$ 954 million, followed by a period of relative stability, reaching US$ 1,092 million by the end of 2022.

Net Fixed Asset Turnover Performance
A sharp contraction in the net fixed asset turnover ratio occurred between 2018 and 2019, falling from 23.99 to 11.62. This decline is primarily attributable to the rapid expansion of net fixed assets and right-of-use assets, which significantly outpaced revenue growth during that interval.
Short-term Volatility and Trough
The ratio reached its lowest point in 2020 at 10.57, indicating a period of decreased asset utilization efficiency. This suggests that the revenue generated per dollar of net fixed assets declined further before the recovery phase began.
Recovery and Efficiency Trends
A positive trend in asset efficiency is observed from 2021 through 2022, with the ratio rising to 12.74 and then to 13.20, respectively. This upward movement indicates that the company is successfully leveraging its expanded asset base to drive higher revenue growth, improving the productivity of its long-term investments.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Total Asset Turnover

IQVIA Holdings Inc., total asset turnover calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
Selected Financial Data (US$ in millions)
Revenues 14,410 13,874 11,359 11,088 10,412
Total assets 25,337 24,689 24,564 23,251 22,549
Long-term Activity Ratio
Total asset turnover1 0.57 0.56 0.46 0.48 0.46
Benchmarks
Total Asset Turnover, Competitors2
AbbVie Inc. 0.42 0.38 — — —
Amgen Inc. 0.38 0.40 — — —
Bristol-Myers Squibb Co. 0.48 0.42 — — —
Danaher Corp. 0.37 0.35 — — —
Eli Lilly & Co. 0.58 0.58 — — —
Gilead Sciences Inc. 0.43 0.40 — — —
Johnson & Johnson 0.51 0.52 — — —
Merck & Co. Inc. 0.54 0.46 — — —
Pfizer Inc. 0.51 0.45 — — —
Regeneron Pharmaceuticals Inc. 0.42 0.63 — — —
Thermo Fisher Scientific Inc. 0.46 0.41 — — —
Vertex Pharmaceuticals Inc. 0.49 0.56 — — —
Total Asset Turnover, Sector
Pharmaceuticals, Biotechnology & Life Sciences 0.47 0.45 — — —
Total Asset Turnover, Industry
Health Care 0.66 0.62 — — —

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

1 2022 Calculation
Total asset turnover = Revenues ÷ Total assets
= 14,410 ÷ 25,337 = 0.57

2 Click competitor name to see calculations.


Between 2018 and 2022, an overall improvement in asset efficiency is observed, characterized by revenue growth that outpaced the expansion of the asset base. While the initial three years showed relative stability in asset utilization, a marked increase in productivity occurred in the final two years of the period.

Revenue Trajectory
Revenues grew from 10,412 million US$ in 2018 to 14,410 million US$ in 2022. A significant acceleration is noted between 2020 and 2021, during which revenues increased from 11,359 million US$ to 13,874 million US$.
Asset Base Expansion
Total assets exhibited a steady upward trend, increasing from 22,549 million US$ in 2018 to 25,337 million US$ in 2022. The growth of the asset base remained linear and moderate compared to the scale of revenue increases.
Total Asset Turnover Performance
The total asset turnover ratio remained range-bound between 0.46 and 0.48 from 2018 through 2020. Starting in 2021, the ratio improved significantly to 0.56, eventually reaching 0.57 in 2022. This progression demonstrates an enhanced capacity to generate revenue per unit of asset, reflecting improved capital efficiency in the latter part of the observed period.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Equity Turnover

IQVIA Holdings Inc., equity turnover calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
Selected Financial Data (US$ in millions)
Revenues 14,410 13,874 11,359 11,088 10,412
Equity attributable to IQVIA Holdings Inc.’s stockholders 5,765 6,042 6,001 6,003 6,714
Long-term Activity Ratio
Equity turnover1 2.50 2.30 1.89 1.85 1.55
Benchmarks
Equity Turnover, Competitors2
AbbVie Inc. 3.36 3.65 — — —
Amgen Inc. 6.77 3.63 — — —
Bristol-Myers Squibb Co. 1.49 1.29 — — —
Danaher Corp. 0.63 0.65 — — —
Eli Lilly & Co. 2.68 3.15 — — —
Gilead Sciences Inc. 1.27 1.28 — — —
Johnson & Johnson 1.24 1.27 — — —
Merck & Co. Inc. 1.29 1.28 — — —
Pfizer Inc. 1.06 1.06 — — —
Regeneron Pharmaceuticals Inc. 0.54 0.86 — — —
Thermo Fisher Scientific Inc. 1.02 0.96 — — —
Vertex Pharmaceuticals Inc. 0.64 0.75 — — —
Equity Turnover, Sector
Pharmaceuticals, Biotechnology & Life Sciences 1.24 1.27 — — —
Equity Turnover, Industry
Health Care 1.69 1.67 — — —

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

1 2022 Calculation
Equity turnover = Revenues ÷ Equity attributable to IQVIA Holdings Inc.’s stockholders
= 14,410 ÷ 5,765 = 2.50

2 Click competitor name to see calculations.


Between 2018 and 2022, a consistent improvement in the efficiency of equity utilization is observed. This trend is characterized by a steady increase in the equity turnover ratio, driven by sustained revenue growth occurring alongside a general contraction of the equity base.

Revenue Performance
Total revenues exhibited a continuous upward trajectory over the five-year period, rising from US$ 10,412 million in 2018 to US$ 14,410 million in 2022. A notable acceleration in growth is evident between 2020 and 2021, where revenues increased by approximately 22%.
Equity Dynamics
Equity attributable to stockholders showed a general downward trend, decreasing from US$ 6,714 million in 2018 to US$ 5,765 million in 2022. After an initial drop in 2019, the equity levels remained relatively stagnant through 2021 before declining again in the final year of the period.
Equity Turnover Efficiency
The equity turnover ratio increased annually, growing from 1.55 in 2018 to 2.50 in 2022. This progression indicates a significant increase in the company's ability to generate sales from its equity investment. The simultaneous increase in revenues and decrease in equity suggests an optimized capital structure or a strategic shift toward higher asset productivity.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?